Because Retatrutide is still undergoing clinical development, it is generally available only through specific professional channels
Gomes A, Souza D, Jos A, Chaves M, Victor J, Oliveira S, et al
Rapid Risk Reduction Seen in First Months The study found that semaglutide was associated with a 38% reduced risk of major adverse cardiovascular events (MACE) within the first 3 months compared to placebo (36 vs 58, respectively) Within the first 6 months, semaglutide was associated with a 41% reduced risk of MACE compared to placebo (67 vs 113, respectively) Notably, at 3 and 6 months, most patients had not yet lost much weight and many were not yet on the full target dose of semaglutide 2.4 mg weekly
If sleep disturbances are troubling, it is worth reviewing all medications and lifestyle factors with your healthcare provider
Store the peptide powder at a minimum of +4C for short-term use, and ideally at -20C or lower for long-term storage